Summary
• ENDRA Life Sciences Inc. (NDRA) shares fell 7.7% in after-hours trading to $6.14 without a clear catalyst.
• Recent clinical feasibility study results for the TAEUS Liver device showed positive outcomes but did not impact trading significantly.
• Q3 financial results reported a loss with an EPS of -1.75, while a private placement raised up to $14.4 million for growth initiatives.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) saw its shares decline by 7.7% in after-hours trading, dropping to $6.14 from the last close of $6.65. This movement occurred without a clear catalyst, as there were no new significant announcements or developments impacting the stock.
Feasibility Study Yields Positive Data
Recently, ENDRA announced preliminary results from a clinical feasibility study of its TAEUS Liver device, which accurately quantifies liver fat fraction—an essential biomarker for metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The study demonstrated encouraging outcomes, but does not appear to have influenced current trading activity significantly.
Recent Developments and Financial Updates
On November 17, ENDRA recapped several milestones while announcing its third-quarter financial results. The report highlighted a private placement that raised up to $14.4 million, which the company plans to leverage towards strategic growth initiatives. Previous earnings figures from Q3 indicated a substantial loss, with an EPS of -1.75, a surprise of 10.3% against the market expectations of -1.95.
Market and Technical Picture
As of the last trading session, NDRA’s RSI stands at a relatively low 37.73, indicating potential oversold conditions. The stock has underperformed notably on a yearly basis, down approximately 42%. Additionally, trading has experienced heightened volatility, with a weekly variance of 9.58% and a monthly volatility of 10.72%. The 10-day average volume of 53,650 contrasts sharply with the 3-month average of 275,842, indicating decreased trading interest recently.
Closing Dynamics
With shares moving without a defined catalyst, the trading action reflects typical market behavior as investors assess the stock’s fundamentals and outcomes from the latest disclosures. Traders will be observing how momentum carries into the next sessions, especially in light of ENDRA’s recent strategic initiatives and the potential implications of its TAEUS technology.